PMA device
Guardant360 CDx
Guardant Health, Inc. · Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP, Class III) · First FDA decision Aug 7, 2020, newest Sep 18, 2026Cancer detection and genomic testing
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
15
PMA pathway
Device trials
0
Naming "Guardant360 CDx"
MAUDE reports
1
Brand "Guardant360 CDx", since 2015
PubMed studies
28
Mentioning "Guardant360 CDx"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Guardant360 CDx
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 15 decisions filed under this name.
- Guardant360 CDxPMA supplement
P200010-S029 · Decided Sep 18, 2026 · 190 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360® CDxPMA supplement
P200010-S032 · Decided Aug 7, 2026 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360 CDxPMA supplement
P200010-S027 · Decided Jun 10, 2026 · 209 days after receipt · Normal 180 Day Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Older decisions: P200010-S021, P200010-S016, P200010-S010, P200010-S009, P200010-S008, P200010-S006, P200010-S002, P200010-S001, P200010
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40210Palmetto GBAUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40278WPS Insurance CorporationUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40226CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in CancerLocal determinationIn effectL40222Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40278WPS Insurance CorporationUpdated Sep 15, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40222Noridian Healthcare Solutions, LLCUpdated Aug 22, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40226CGS Administrators, LLCUpdated Aug 21, 2025
- MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerProposed local determinationProposedDL40210Palmetto GBAUpdated Aug 18, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Guardant360 CDx", any status and sponsor, newest update first.
No registered device study names "Guardant360 CDx".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Guardant360 CDx", and for the whole product code for context.
This brand
1 reports: 0 malfunction, 1 injury, 0 death
Whole product code PQP
14 reports: 11 malfunction, 2 injury, 0 death
Newest reports for this brand
- GUARDANT360 CDXInjury
3012090384-2023-00001 · Received May 19, 2023 · Event dated Jan 11, 2023
Device type: Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System (PQP)
Device problem as coded: False Positive Result
Patient problem as coded: Insufficient Information
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Guardant360 CDx"[tiab]. The summary above synthesizes these.
- Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
Felip E, Cho BC, Gutiérrez V, et al. · Ann Oncol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.
Bauml JM, Li BT, Velcheti V, et al. · Lung Cancer · 2022
- Liquid biopsy in lung cancer.
Kitagawa S, Seike M · Jpn J Clin Oncol · 2025Review
- Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non-Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02.
Qi Z, Tokuhiro S, Odegaard JI, et al. · J Mol Diagn · 2025Clinical Trial, Phase II, Multicenter Study
- Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence.
Abbasi HQ, Maryyum A, Khan AM, et al. · Int J Surg · 2023Letter
- Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
Turner NC, Mayer EL, Park YH, et al. · Lancet Oncol · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Clinical Validation of Companion Diagnostics for the Selection of Patients with Non-Small Cell Lung Cancer Tumors Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutations for Treatment with Amivantamab.
Jatkoe T, Wang S, Odegaard JI, et al. · J Mol Diagn · 2022Research Support, Non-U.S. Gov't
- HER2 expression in urothelial carcinoma, a systematic literature review.
Scherrer E, Kang A, Bloudek LM, et al. · Front Oncol · 2022Systematic Review
- Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C, Bauer S, Gómez-Peregrina D, et al. · Ann Oncol · 2023Clinical Trial, Phase III, Research Support, N.I.H., Extramural
- Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
Koh Y, Nakano K, Katayama K, et al. · Int J Urol · 2022Research Support, Non-U.S. Gov't
- Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.
Zwierenga F, Muntinghe-Wagenaar MB, Rozendal P, et al. · Target Oncol · 2025
- The Opportunities and Challenges of Molecular Tagging Next-Generation Sequencing in Liquid Biopsy.
De Luca G, Dono M · Mol Diagn Ther · 2021
Other devices of this type
Also filed under product code PQP.
- FoundationOne CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOne Liquid CDxFoundation Medicine, Inc. · PMA 2026
- Oncomine Dx Target TestLife Technologies Corporation · PMA 2025
- Oncomine Dx Express TestLife Technologies Corporation · PMA 2026
- xT CDxTempus AI, Inc. · PMA 2026
- TruSight Oncology ComprehensiveIllumina, Inc. · PMA 2026
- FoundationOne®Liquid CDxFoundation Medicine, Inc. · PMA 2026
- FoundationOneCDx (F1CDx)Foundation Medicine, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.